Aligos Therapeutics Inc
(ALGS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -29,802 | -34,863 | -87,679 | -59,787 | -41,746 |
| Depreciation Amortization | 348 | 590 | 2,645 | 1,870 | 1,189 |
| Accounts payable and accrued liabilities | -476 | -4,475 | -1,301 | -5,453 | -3,698 |
| Other Working Capital | -1,383 | -5,494 | -9,525 | -9,232 | -3,030 |
| Other Operating Activity | -10,926 | 21,496 | 16,863 | 16,263 | 11,282 |
| Operating Cash Flow | $-42,239 | $-22,746 | $-78,997 | $-56,339 | $-36,003 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -48,573 | -88,573 | 45,000 | 45,000 | 44,990 |
| PPE Investments | -76 | -69 | -19 | -12 | 7 |
| Investing Cash Flow | $-48,649 | $-88,642 | $44,981 | $44,988 | $44,997 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -35 | -19 | -96 | -92 | -71 |
| Common Stock Issued | 297 | N/A | 88,424 | 484 | 484 |
| Financing Cash Flow | $262 | $-19 | $88,328 | $392 | $413 |
| Beginning Cash Position | 135,774 | 135,774 | 81,462 | 81,462 | 81,463 |
| End Cash Position | 45,148 | 24,367 | 135,774 | 70,503 | 90,870 |
| Net Cash Flow | $-90,626 | $-111,407 | $54,312 | $-10,959 | $9,407 |
| Free Cash Flow | |||||
| Operating Cash Flow | -42,239 | -22,746 | -78,997 | -56,339 | -36,003 |
| Capital Expenditure | -76 | -69 | -19 | -12 | 7 |
| Free Cash Flow | -42,315 | -22,815 | -79,016 | -56,351 | -35,996 |